Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:FUSN

Fusion Pharmaceuticals (FUSN) Stock Price, News & Analysis

Fusion Pharmaceuticals logo

About Fusion Pharmaceuticals Stock (NASDAQ:FUSN)

Advanced Chart

Key Stats

Today's Range
$21.55
$21.55
50-Day Range
$21.38
$21.55
52-Week Range
$2.31
$21.60
Volume
N/A
Average Volume
1.69 million shs
Market Capitalization
$1.83 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive FUSN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

FUSN Stock News Headlines

Fusion Pharma Stock Price History
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
Fusion Finance Ltd (FUSN)
Fusion Pharma (FUSN) Earnings Dates & Reports
Acquisition of Fusion Pharmaceuticals Completed
See More Headlines

FUSN Stock Analysis - Frequently Asked Questions

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) announced its earnings results on Tuesday, November, 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.13. The company earned $0.33 million during the quarter. Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative trailing twelve-month return on equity of 48.74%.

Fusion Pharmaceuticals (FUSN) raised $126 million in an initial public offering on Friday, June 26th 2020. The company issued 8,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Fusion Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO), Super Micro Computer (SMCI) and ServiceNow (NOW).

Company Calendar

Last Earnings
11/09/2021
Today
7/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:FUSN
CIK
1805890
Fax
N/A
Employees
101
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.42)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$94.90 million
Net Margins
-4,136.55%
Pretax Margin
-5,084.07%
Return on Equity
-48.74%
Return on Assets
-36.87%

Debt

Debt-to-Equity Ratio
0.21
Current Ratio
10.64
Quick Ratio
10.64

Sales & Book Value

Annual Sales
$2.07 million
Price / Sales
885.53
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.07 per share
Price / Book
7.02

Miscellaneous

Outstanding Shares
85,060,000
Free Float
78,468,000
Market Cap
$1.83 billion
Optionable
Optionable
Beta
-0.69
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:FUSN) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners